Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Ka Mutations [Seeking Alpha]
Relay Therapeutics, Inc. (RLAY)
Company Research
Source: Seeking Alpha
Follow Summary Relay Therapeutics' Dynamo platform combines machine learning and physics-based simulation to target dynamic protein conformations for oncology and genetic disease therapies. RLY-2608 targets PI3Ka-mutated HR+/HER2- breast cancer, with promising Phase 2 results and potential approval by 2026-2027. The company's RLY-4008 targets FGFR2-altered cholangiocarcinoma, and it is seeking pivotal trials and a commercialization partner to unlock broader market potential. Relay has up to 3.3 years cash runway (including the recent equity raise), which, I believe, is sufficient to cover the RLY-2608's upcoming milestones. Despite trial disappointments and potential dilution risks, RLAY's promising pipeline and robust financials justify a "buy" rating for long-term investors. RichLegg/E+ via Getty Images Relay Therapeutics ( NASDAQ: RLAY ) is a clinical-stage biotech that uses its proprietary Dynamo drug discovery platform. This employs computational technology such
Show less
Read more
Impact Snapshot
Event Time:
RLAY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLAY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLAY alerts
High impacting Relay Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLAY
News
- Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $21.00 price target on the stock.MarketBeat
- Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion [Seeking Alpha]Seeking Alpha
- Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $28.00 price target on the stock.MarketBeat
- Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target raised by analysts at HC Wainwright from $18.00 to $19.00. They now have a "buy" rating on the stock.MarketBeat
- Relay Therapeutics Announces Pricing of Public Offering of Common Stock [Yahoo! Finance]Yahoo! Finance
RLAY
Earnings
- 8/6/24 - Beat
RLAY
Sec Filings
- 9/11/24 - Form 8-K
- 9/11/24 - Form 424B5
- 9/9/24 - Form 424B5
- RLAY's page on the SEC website